WHAT SERVICE ARE YOU LOOKING FOR?
Sequencing Panels
Choose the panel that corresponds to the pathology you want to test your patient for.
Channelopathies and cardiac arrhythmias
Aortic, vascular, and connective tissue diseases
Congenital cardiopathies and pulmonary hypertension
Dyslipidemias – Atherosclerosis
Cardiomyopathy
Rare diseases with cardiac affectation (Cardiomyopathy)
Channelopathies and cardiac arrhythmias
Aortic, vascular, and connective tissue diseases
Congenital cardiopathies and pulmonary hypertension
Dyslipidemias – Atherosclerosis
Exome analysis
Exome sequencing is a powerful tool for diagnosing genetically inherited diseases that massively and simultaneously studies the protein-coding regions of our genes.
FASTQ: includes preparing and sequencing the samples and obtaining raw sequencing data in fastq format. Deliverable: fastq files.
TAT [turnaround time]: 2 weeks
FASTQ + annotated variants: includes the bioinformatics processing of raw sequencing data to obtain a list of the annotated variants that have been detected in each sample. Deliverables: fastq files, tables of annotated variants, and coverage statistics.
TAT [turnaround time]: 3 weeks
FASTQ + annotated variants + interpretation: Once the annotated variant tables have been generated, the client can request the advanced clinical interpretation of variants located in genes associated with inherited heart disease (380 genes). Deliverables: fastq files, tables of annotated variants, coverage statistics, and complete clinical report for the 380 genes.
TAT [turnaround time]: 5 weeks
Whole-genome array
We offer array-based molecular cytogenetics services of CNVs to study unbalanced chromosomal aberrations whose size exceeds the capabilities of the used sequencing techniques at the genomic level.
MLPA
The MLPA technique is used to detect copy number variants (insertions/deletions) that affect a part or a whole gene, which are frequent causes of certain pathologies with a genetic basis.
Mitochondrial Genome
Diagnostic service based on the sequencing of the mitochondrial genome and characterization of variants (point mutations and CNVs) that may be a cause of cardiac, neurological or metabolic diseases.